Key facts
- Axiom (Biotechnology)’s last known valuation is $121.0M (Apr 2025).
- It has raised $30.0M; the latest was Early Stage VC ($15.0M) in Apr 2025.
- Notable investors include Abstract Ventures, CRV, Jeff Dean, Amplify Partners, Dimension (United States) — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Axiom (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Axiom (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Axiom (Biotechnology)
Developer of a biotechnology platform designed to help scientists predict and mitigate drug toxicity earlier in the development process. The company offers AI models trained on primary human liver biology, enabling pharmaceutical researchers to identify liver injury risks with greater accuracy, reduced cost, and without the use of animal testing.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Employees
- 25
- Website
- axi.om/
- Ownership
- Privately Held (backing)
Axiom (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axiom (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axiom (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.